【正文】 Others fear that Pfizer s tactics may drive up costs for the employers who sponsor healthplans, thanks to the plexities of copayment schemes, and confuse patients lectured foryears about the merits of ，由于共同支付計劃很復雜，輝瑞的戰(zhàn)術會增加雇主門支付健康計劃的成本，也讓患者。All this may raise Pfizer s sales by nearly $500m in the first half of 2012 pared with whatthey would otherwise have been, says Tim Anderson of BernsteinResearch, with revenuesthen falling after the 180 days are Anderson認為，所有這些舉措將使得輝瑞2012年上半年的銷售額比不采取措施時增加近5億美元，總收入在180天市場獨占期后會下降。Patients with a special discount card from Pfizer will make copayments of just $4 for a month s worth of the originalLipitor, pared with about $10 for many generic ，若使用一種特殊打折卡，通過共同支付方式，只花4美元就可以獲得一個月用量的立普妥專利藥，而其他仿制品需要花費約10美元。So Ranbaxy faces not one, but two ，蘭伯西的對手是兩個，而非一個。According to BernsteinResearch, under the deal between the two drugmakers Pfizer willreceive about 70% of Watson s revenues from its approved copy of ，在此交易期間，華生公司獲得立普妥的仿制權，輝瑞將獲得華生公司年收入的70%。To encourage generics makers to challenge patents on drugs, and introduce cheapercopies，為了鼓勵非專利制藥企業(yè)挑戰(zhàn)藥品專利、生產價錢更低的仿制藥，an American law passed in 1984 says that the first one to do so will get a 180day exclusivityperiod，美國于1984年通過一項法案，其中提到 第一個挑戰(zhàn)成功的仿制藥企能獲得180天市場獨占期，in which no other generics maker can sell versions of the drug in question, as Ranbaxysupposedly won with ，就像蘭伯西獲得立普妥仿制藥的生產權一樣。American and European regulators are looking into these 美國和歐洲的監(jiān)管部門也開始調查這些協(xié)議。Another tactic is payfordelay , in which a drugmaker facing a legal challenge to itspatent pays its wouldbe petitor to put off introducing its cheaper 有償延遲 協(xié)議，也就是說在專利訴訟時，制藥企業(yè)會付給未來競爭對手一筆錢，以延遲價錢更低的仿制藥進入市場。More important, researchbased drug firms are using a variety of tactics to make the patentcliff slope more ，以研發(fā)為基礎的制藥公司正使用各種方法緩沖 專利懸崖 效應。But generics makers may face delays getting their cheaper versions to ，非專利制藥企業(yè)卻發(fā)現仿制藥上市一拖再拖。Patients and healthcare payers should reap the ，而輝瑞的收入會縮水。In all, blockbusters with a bined $170 billion in annual sales will go offpatent by ，多種 重磅炸彈 藥物的專利都將失效。二．Drugmakers Cliffhanger制藥企業(yè) 懸念Big Pharma struggles to protect its blockbusters as they lose patent protection大型制藥企業(yè)艱難保護著專利失效的 重磅炸彈 藥物FOR some years the big drugmakers have been dreading an approaching patent cliff —aslump in sales as the patents on their most popular pills expire or are struck down by legalchallenges, with few new potential blockbusters to take their ，大型制藥企業(yè)一直擔心 專利懸崖 出現——最暢銷藥品的專利到期或專利因訴訟而中止，而市場上鮮有新的 重磅炸彈 藥物，這時企業(yè)的銷售額將會銳減?？射J教育官網But outrage over Facebook s behaviour could spur Congress into action it willcertainly not be lost on regulators in Europe who are scrutinising the social network sprivacy record ，而正在審閱該社交網隱私記錄的歐洲協(xié)調員們也必然會給予這些不滿的呼聲以相應的重視。The audits can be used to tweak the framework in the light of new ，這些審核有助于打破原本框架。There is a clear pattern 。Among other things, the pany will now have to seek consumers approval before itchanges the way it shares their it has agreed to an independent privacy auditevery two years for the next 20 ，在改變用戶信息共享方式前，它還必須征詢用戶的同意，并且它也同意在未來二十年里每兩年進行一次獨立的隱私審核。Then he confessed that it could still do better and said he had hired two new chief ，他承認確實有一些地方需要改進，并說明他已經雇用了兩名新的 首席隱私官。In a blog post published the same day, Mark Zuckerberg, Facebook s boss, tried to play downthe impact of the ，臉譜老板Mark Zuckerberg在一篇博文上極力淡化這份協(xié)議的影響。The settlement does not constitute an admission by Facebook that it has broken the 。Announcing the agreement, the FTC said it had found a number of cases where Facebook hadmade claims that were unfair and deceptive, and violated federal ，FTC說發(fā)現有好幾回臉譜的聲明都是 不公平，虛假并觸犯聯邦法 的，For instance, it passed on personally identifiable information to advertisers, even though itsaid it would not do ，它把用戶身份信息透露給廣告商，但是嘴上卻聲稱不會做此類事情。To clear the way for its blockbuster flotation, the firm first needs to resolve its privacytussles with regulators in America and ，臉譜網必須首先解決與美國和歐洲協(xié)調員關于用戶隱私的爭端，因此這周它公開了商談意向。The regulator s findings e at a sensitive time for Facebook, which is said to be preparingfor an initial public offering next year that could value it at around $100 。It is also notable because it appears to be part of a broader attempt by the FTC to craft anew privacy framework to deal with the swift rise of social networks in ，那就是創(chuàng)建一個新的隱私框架以應對美國快速攀升的社交網用戶。On November 29th America s Federal Trade Commission announced that it hadreached a draft settlement with the giant social network over allegations that it hadmisled people about its use of their personal 、濫用用戶個人信息的控訴初步達成解決方案。For now, it is more profitable to treat fat patients than to try to make them ，治療肥胖患者還是要比讓他們減肥更有利可圖。Qnexa bines two treatments that are already on the 。However, the agency may yet reject the 。The FDA rejected Vivus s Qnexa in 2010 over concerns for the safety of pregnant women andthe quickening of patients heart ，因為擔心該藥對孕婦的安全造成傷害，擔心該藥會加快患者的心率。It has been 13 years since the FDA approved a prescription diet 。There is some scepticism about his chances of success: The fact that banding is not as goodas bypass has been known by everybody except the PR firms for the band, says LeeKaplan, director of the Weight Centre at Massachusetts General ：“事實上使用束帶不必胃繞道手術好，所有人都知道，除了束帶的公關公司，”馬薩諸塞州中心醫(yī)院體重中心主任Lee Kaplan如是說。In January David Pyott, Allergan s chief executive, said he would scrap an effort to marketthe band for ，Allergan公司首席執(zhí)行官David Pyott說，他將放棄在年輕人束帶市場的努力。Some patients have had bands removed because they slipped or proved ，因為束帶打滑或者沒有效果。Allergan has captured about 70% of the worldwide market for gastric bands and balloons, 可銳教育官網butsales are now %，但是如今銷量卻有所下降。Allergan, best known for selling Botox, has tried to use its LapBand to tap the ，嘗試用產品LapBand打入減肥市場。Bariatric surgery can lead to weight loss in the long can make money fromall bariatric procedures, including gastric bypasses , but the gastric band is a rareexample of an opportunity for devicemakers to profit from weight 。This